Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

NCT02485535 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
de Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome
Secondary Acute Myeloid Leukemia
Secondary Myelodysplastic Syndrome

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Selinexor

Sponsor

University of Chicago

Collaborators

[object Object]